FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206483807> ?p ?o ?g. }

• W3206483807 endingPage "1266" @default.
• W3206483807 startingPage "1266" @default.
• W3206483807 abstract "The follow-up schedule for individuals with eyes treated with anti-vascular endothelial growth factor agents for proliferative diabetic retinopathy (PDR) requires that patients return frequently for monitoring and repeated treatment. The likelihood that a patient will comply should be a consideration in choosing a treatment approach.To describe completion of scheduled examinations among participants assigned to intravitreous injections of ranibizumab for PDR in a multicenter randomized clinical trial.This post hoc analysis evaluates data from a randomized clinical trial conducted at 55 US sites among 305 adults with proliferative diabetic retinopathy enrolled between February and December 2012. Both eyes were enrolled for 89 participants (1 eye to each study group), with a total of 394 study eyes. The final 2-year visit was completed in January 2015. Data were analyzed from April 2019 to July 2021.Ranibizumab injections for PDR or macular edema.A long lapse in care of 8 or more weeks past a scheduled examination, dropout from follow-up, visual acuity at 5 years.Among 170 participants, the median age was 51 years, and 44.7% were female. Through 5 years of follow-up, 94 of 170 participants (55.3%) had 1 or more long lapse in care. Median time to the first long lapse was 210 weeks, and 69 of 94 participants (73.4%) returned for examination after the first long lapse. Fifty of 170 participants (29.4%) dropped out of follow-up by 5 years. Among the 120 participants who completed the 5-year examination, median change from baseline in visual acuity was -2 letters for participants who had 1 or more long lapse compared with +5 letters for those without a long lapse (P = .02). After multivariable adjustment, the odds ratio (95% CI) for baseline associations with 1 or more long lapse was 1.21 (1.03-1.43) for each 5-letter decrement in visual acuity score, 2.19 (1.09-4.38) for neovascularization of the disc and elsewhere, and 3.48 (1.38-8.78) for no prior laser treatment for diabetic macular edema.Over 5 years, approximately half of the participants assigned to ranibizumab for PDR had a long lapse in care despite substantial effort by the DRCR Retina Network to facilitate timely completion of examinations. The likelihood of a long lapse in care during long-term follow-up needs to be considered when choosing treatment for PDR.ClinicalTrials.gov Identifier: NCT01489189." @default.
• W3206483807 created "2021-10-25" @default.
• W3206483807 creator A5011697010 @default.
• W3206483807 creator A5015264417 @default.
• W3206483807 creator A5023376839 @default.
• W3206483807 creator A5029257998 @default.
• W3206483807 creator A5044636736 @default.
• W3206483807 creator A5067005074 @default.
• W3206483807 creator A5076306018 @default.
• W3206483807 creator A5091736159 @default.
• W3206483807 date "2021-12-01" @default.
• W3206483807 modified "2023-10-17" @default.
• W3206483807 title "Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy" @default.
• W3206483807 cites W1971721633 @default.
• W3206483807 cites W2046807902 @default.
• W3206483807 cites W2178156144 @default.
• W3206483807 cites W2179367951 @default.
• W3206483807 cites W2610772121 @default.
• W3206483807 cites W2611235917 @default.
• W3206483807 cites W2792419881 @default.
• W3206483807 cites W2794935335 @default.
• W3206483807 cites W2809898434 @default.
• W3206483807 cites W2883798682 @default.
• W3206483807 cites W2885537851 @default.
• W3206483807 cites W2886506590 @default.
• W3206483807 cites W2921836527 @default.
• W3206483807 cites W2962378670 @default.
• W3206483807 cites W3003784804 @default.
• W3206483807 cites W3005239446 @default.
• W3206483807 cites W3012859928 @default.
• W3206483807 cites W3014689067 @default.
• W3206483807 cites W4232979084 @default.
• W3206483807 doi "https://doi.org/10.1001/jamaophthalmol.2021.4103" @default.
• W3206483807 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8532036" @default.
• W3206483807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34673898" @default.
• W3206483807 hasPublicationYear "2021" @default.
• W3206483807 type Work @default.
• W3206483807 sameAs 3206483807 @default.
• W3206483807 citedByCount "10" @default.
• W3206483807 countsByYear W32064838072022 @default.
• W3206483807 countsByYear W32064838072023 @default.
• W3206483807 crossrefType "journal-article" @default.
• W3206483807 hasAuthorship W3206483807A5011697010 @default.
• W3206483807 hasAuthorship W3206483807A5015264417 @default.
• W3206483807 hasAuthorship W3206483807A5023376839 @default.
• W3206483807 hasAuthorship W3206483807A5029257998 @default.
• W3206483807 hasAuthorship W3206483807A5044636736 @default.
• W3206483807 hasAuthorship W3206483807A5067005074 @default.
• W3206483807 hasAuthorship W3206483807A5076306018 @default.
• W3206483807 hasAuthorship W3206483807A5091736159 @default.
• W3206483807 hasBestOaLocation W32064838072 @default.
• W3206483807 hasConcept C118487528 @default.
• W3206483807 hasConcept C126322002 @default.
• W3206483807 hasConcept C134018914 @default.
• W3206483807 hasConcept C141071460 @default.
• W3206483807 hasConcept C168563851 @default.
• W3206483807 hasConcept C2776694085 @default.
• W3206483807 hasConcept C2777802072 @default.
• W3206483807 hasConcept C2778257484 @default.
• W3206483807 hasConcept C2779829184 @default.
• W3206483807 hasConcept C2781100027 @default.
• W3206483807 hasConcept C535046627 @default.
• W3206483807 hasConcept C555293320 @default.
• W3206483807 hasConcept C67761136 @default.
• W3206483807 hasConcept C71924100 @default.
• W3206483807 hasConceptScore W3206483807C118487528 @default.
• W3206483807 hasConceptScore W3206483807C126322002 @default.
• W3206483807 hasConceptScore W3206483807C134018914 @default.
• W3206483807 hasConceptScore W3206483807C141071460 @default.
• W3206483807 hasConceptScore W3206483807C168563851 @default.
• W3206483807 hasConceptScore W3206483807C2776694085 @default.
• W3206483807 hasConceptScore W3206483807C2777802072 @default.
• W3206483807 hasConceptScore W3206483807C2778257484 @default.
• W3206483807 hasConceptScore W3206483807C2779829184 @default.
• W3206483807 hasConceptScore W3206483807C2781100027 @default.
• W3206483807 hasConceptScore W3206483807C535046627 @default.
• W3206483807 hasConceptScore W3206483807C555293320 @default.
• W3206483807 hasConceptScore W3206483807C67761136 @default.
• W3206483807 hasConceptScore W3206483807C71924100 @default.
• W3206483807 hasIssue "12" @default.
• W3206483807 hasLocation W32064838071 @default.
• W3206483807 hasLocation W32064838072 @default.
• W3206483807 hasLocation W32064838073 @default.
• W3206483807 hasOpenAccess W3206483807 @default.
• W3206483807 hasPrimaryLocation W32064838071 @default.
• W3206483807 hasRelatedWork W2062091766 @default.
• W3206483807 hasRelatedWork W2091729420 @default.
• W3206483807 hasRelatedWork W2178156144 @default.
• W3206483807 hasRelatedWork W2281889375 @default.
• W3206483807 hasRelatedWork W2790038519 @default.
• W3206483807 hasRelatedWork W3028901250 @default.
• W3206483807 hasRelatedWork W3134304631 @default.
• W3206483807 hasRelatedWork W4214825361 @default.
• W3206483807 hasRelatedWork W4223448639 @default.
• W3206483807 hasRelatedWork W4285812041 @default.
• W3206483807 hasVolume "139" @default.
• W3206483807 isParatext "false" @default.
• W3206483807 isRetracted "false" @default.

• next